


PRODUCT: LCL161

ALTERNATE NAMES: LCL-161, lcl161, LCL 161, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, XIAP Inhibitor, IAP inhibitor

CATALOG#: B1601-5, -25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₆H₃₃FN₄O₃S

MOLECULAR WEIGHT: 500.63

CAS NUMBER: 1005342-46-0

APPEARANCE: White solid powder

SOLUBILITY: Ethanol: 20 mg/ml warmed (39.94 mM)
DMSO: 100 mg/ml (199.74 mM)

PURITY: 99.72% by HPLC

STORAGE: Store at -20°C. Protect from air and light.

DESCRIPTION: LCL161, a SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). Phase 2

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES: 1. Weisberg E, et al. Leukemia, 2010, 24(12), 2100-2109.2.
2. Houghton PJ, et al. Pediatr Blood Cancer, 2012, 58(4), 636-639.

RELATED PRODUCTS:

- Birinapant (2597)
- Embelin (B1600)

USAGE: *FOR RESEARCH USE ONLY! Not to be used in humans*